Furthermore, certain medications, such as GLP1-RA and sodium-glucose cotransporter 2 inhibitors, have been found to have a beneficial role in CVD, HF, and CKD, independent of their glucose-lowering effects. This evidence concerns the gene GCG and chronic kidney disease.